Your browser doesn't support javascript.
loading
Improving keratoconus management with central cor neal regularization and corneal collagen cross-linking protocol treatment.
Napolitano, R; Tonti, E; Cifariello, F; Sabater-Cruz, N; Spadea, L.
Afiliação
  • Napolitano R; Eye Clinic, Policlinico Umberto 1, "Sapienza" University of Rome, Italy.
  • Tonti E; Eye Clinic, Policlinico Umberto 1, "Sapienza" University of Rome, Italy.
  • Cifariello F; Casa di Cura "Villa Maria", Campobasso, Italy.
  • Sabater-Cruz N; Institut Clinic d'Oftalmologia, Barcelona, Spain.
  • Spadea L; Eye Clinic, Policlinico Umberto 1, "Sapienza" University of Rome, Italy.
Clin Ter ; 173(3): 274-279, 2022 May 25.
Article em En | MEDLINE | ID: mdl-35612343
Purpose: To evaluate safety and efficacy of customized central corneal regularization (CCR), together with simultaneous accelerated corneal collagen cross-linking (A-CXL) - CCR-CXL protocol, to treat keratoconus-related corneal ectasia. Design: Retrospective, comparative observational case series. Methods: Patients that had undergone combined CCR-CXL protocol. Main inclusion criteria were keratoconus visual acuity deterioration and contact lens intolerance. All patients underwent complete ophthalmological evaluation, corrected distance visual acuity (CDVA) and Scheimpflug-corneal tomography. Central corneal regularization was performed by ablation using flying spot laser. Subsequently, the stroma was saturated with 0.17% riboflavin-5-phosphate added every 2 minutes, followed by A-CXL 9 mW/cm2 for 10 minutes. CDVA, medium keratometry value (Kmed), and total corneal morphological irregularity index (CMI) of patients were analyzed before surgery and after 1, 3 and 12 months. A P value of .05 or less was considered statistically significant. Results: 46 eyes of 39 keratoconus patients were treated. At 1 month, the mean CDVA (LogMar) increased from 0.19 ± 0.02 to 0.12 ± 0.02 (P < .05), and the difference remained stable at month 12. Kmax decrease was statistically significant from 57.02 ± 5.65 to 50.21 ± 4.48 (P < .05). CMI decreased significantly from 47.8 ± 2.84 to 30.1 ± 2.4 (P < .01). Conclusions: CCR-CXL protocol is safe and effective in arresting keratectasia progression and increasing corneal optic regularity in keratoconus. These findings showed a significant improvement in CDVA, keratometry values and corneal optical aberrations after being treated with the CCR-CXL protocol.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fotoquimioterapia / Ceratocone Tipo de estudo: Guideline / Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Clin Ter Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Itália

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fotoquimioterapia / Ceratocone Tipo de estudo: Guideline / Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Clin Ter Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Itália